Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
International journal of molecular sciences · 2025
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Alicia Simalie OmbredaneLaboratory of Bioactive Compounds and Nanobiotechnology (LCBNano), University of Brasilia, Campus Universitário-Centro Metropolitano, Ceilandia Sul, Brasilia 72220-275, Brazil.ORCID 0000-0002-0937-4792
Natália Ornelas MartinsLaboratory of Bioactive Compounds and Nanobiotechnology (LCBNano), University of Brasilia, Campus Universitário-Centro Metropolitano, Ceilandia Sul, Brasilia 72220-275, Brazil.ORCID 0000-0001-5643-7154
Gabriela Mara Vieira de SouzaLaboratory of Bioactive Compounds and Nanobiotechnology (LCBNano), University of Brasilia, Campus Universitário-Centro Metropolitano, Ceilandia Sul, Brasilia 72220-275, Brazil.
Victor Hugo Sousa AraujoLaboratory of Bioactive Compounds and Nanobiotechnology (LCBNano), University of Brasilia, Campus Universitário-Centro Metropolitano, Ceilandia Sul, Brasilia 72220-275, Brazil.
Ísis O SzlachetkaPost-Graduation Program in Nanoscience and Nanobiotechnology, University of Brasilia, Campus Universitário Darcy Ribeiro, Brasilia 70910-900, Brazil.
Sebastião William da SilvaPost-Graduation Program in Nanoscience and Nanobiotechnology, University of Brasilia, Campus Universitário Darcy Ribeiro, Brasilia 70910-900, Brazil.ORCID 0000-0003-4483-9687
Márcia Cristina Oliveira da RochaPost-Graduation Program in Nanoscience and Nanobiotechnology, University of Brasilia, Campus Universitário Darcy Ribeiro, Brasilia 70910-900, Brazil.
Andressa Souza de OliveiraGraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Health Sciences Faculty, University of Brasilia, Brasilia 70910-900, Brazil.ORCID 0000-0001-5508-1184
Cleonice Andrade HolandaGraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Health Sciences Faculty, University of Brasilia, Brasilia 70910-900, Brazil.
Luiz Antonio Soares RomeiroGraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Health Sciences Faculty, University of Brasilia, Brasilia 70910-900, Brazil.ORCID 0000-0001-5679-0820
Elysa Beatriz de Oliveira DamasLaboratory of Bioactive Compounds and Nanobiotechnology (LCBNano), University of Brasilia, Campus Universitário-Centro Metropolitano, Ceilandia Sul, Brasilia 72220-275, Brazil.
Ricardo Bentes AzevedoPost-Graduation Program in Nanoscience and Nanobiotechnology, University of Brasilia, Campus Universitário Darcy Ribeiro, Brasilia 70910-900, Brazil.ORCID 0000-0002-2137-9588
Graziella Anselmo JoanittiLaboratory of Bioactive Compounds and Nanobiotechnology (LCBNano), University of Brasilia, Campus Universitário-Centro Metropolitano, Ceilandia Sul, Brasilia 72220-275, Brazil.ORCID 0000-0002-6888-1284
Funding
Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Distrito Federal 001National Council for Scientific and Technological Development 001Universidade de Brasília 001
6 · The paper itself
Abstract
Combination therapy integrated with nanotechnology offers a promising alternative for breast cancer treatment. The inclusion of pequi oil, anacardic acid (AA), and docetaxel (DTX) in a nanoemulsion can amplify the antitumor effects of each molecule while reducing adverse effects. Therefore, the study aims to develop pequi oil-based nanoemulsions (PeNE) containing DTX (PDTX) or AA (PAA) and to evaluate their cytotoxicity against triple-negative breast cancer cells (4T1) in vitro. The PeNE without and with AA (PAA) and DTX (PDTX) were prepared by sonication and characterized by ZetaSizer
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Combinatory Effect of Pequi Oil ( · full record | Socratic